{"id":387434,"date":"2020-11-24T07:03:29","date_gmt":"2020-11-24T12:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387434"},"modified":"2020-11-24T07:03:29","modified_gmt":"2020-11-24T12:03:29","slug":"sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/","title":{"rendered":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8211; Discussion of STRO-002 Data and Program Expansion at 5pm ET \/ 2pm PT on Dec. 3rd &#8211;<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SOUTH SAN FRANCISCO, Calif.<\/span>, <span class=\"xn-chron\">Nov. 24, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,\u00a0 announced today that it will host a live webcast event to provide a clinical update from the company&#8217;s ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolR\u03b1) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of <span class=\"xn-chron\">Oct. 30, 2020<\/span>. The company will also give an update on the program expansion cohorts in ovarian and endometrial cancer. The virtual KOL Discussion of STRO-002 Data will be held on <span class=\"xn-chron\">Thursday, Dec. 3, 2020<\/span>, at <span class=\"xn-chron\">5pm ET<\/span> \/ <span class=\"xn-chron\">2pm PT<\/span>.<\/p>\n<p>The data will be presented and discussed by Principal Investigators from two STRO-002 clinical trial sites: <\/p>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-person\">Lainie P. Martin<\/span>, M.D. &#8211; Leader, Gynecology\/Oncology Program and Associate Professor of Medicine at Hospital of the <span class=\"xn-org\">University of Pennsylvania<\/span>; Dr. Martin is also a member of Sutro&#8217;s Clinical Advisory Board<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>R. <span class=\"xn-person\">Wendel Naumann<\/span>, M.D. &#8211; Professor &amp; Director of Gynecologic Oncology Research and Associate Medical Director of Clinical Trials at Levine Cancer Institute \u2013 Atrium Health in <span class=\"xn-location\">Charlotte, North Carolina<\/span>; Dr. Naumann is also a member of Sutro&#8217;s Clinical Advisory Board<\/li>\n<\/ul>\n<p>To register and access the Zoom link for this event click <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990982-1&amp;h=3110787264&amp;u=https%3A%2F%2Fsoleburytrout.zoom.us%2Fwebinar%2Fregister%2FWN_7uYWT4c6Sp-u_zDHa2VxAg&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a> or email <span class=\"xn-person\">Annie Chang<\/span> at <a target=\"_blank\" href=\"mailto:ajchang@sutrobio.com\" rel=\"nofollow noopener noreferrer\">ajchang@sutrobio.com<\/a>.<\/p>\n<p>An archived recording of the event will be available through the Company Presentation page of the Investor section of the company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990982-1&amp;h=254733874&amp;u=http%3A%2F%2Fwww.sutrobio.com%2F&amp;a=http%3A%2F%2Fwww.sutrobio.com\" rel=\"nofollow noopener noreferrer\">http:\/\/www.sutrobio.com<\/a> for approximately 30 days.<\/p>\n<p>\n        <b>About the Phase 1 Trial of STRO-002 in Ovarian Cancer<br \/><\/b>STRO-002-GM1, the Phase 1 open-label, multicenter, dose escalation trial with dose expansion of STRO-002, has completed enrollment. Follow-up is ongoing and will continue to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-002 in adults with advanced epithelial ovarian cancer, including fallopian and primary peritoneal cancer. The trial is registered with clinicaltrials.gov identifier NCT03748186. Sutro discovered, developed and manufactures STRO-002 using its proprietary XpressCF\u00ae cell-free protein synthesis and XpressCF+\u2122 site-specific conjugation technologies.<\/p>\n<p>\n        <b>About Sutro Biopharma<br \/><\/b>Sutro Biopharma, Inc., located in <span class=\"xn-location\">South San Francisco<\/span>, is\u00a0a clinical-stage drug discovery, development\u00a0and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.<\/p>\n<p>Sutro&#8217;s proprietary and integrated cell-free protein synthesis platform XpressCF\u00ae and site-specific conjugation platform XpressCF+\u2122 led to the discovery of STRO-001 and STRO-002, Sutro&#8217;s first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in <span class=\"xn-chron\">October 2018<\/span>. STRO-002 is a folate receptor alpha (FolR\u03b1)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro&#8217;s XpressCF\u00ae and XpressCF+\u2122 technology platforms. A third program, CC-99712 (BCMA-targeting ADC), which is part of Sutro&#8217;s collaboration with Bristol Myers Squibb (formerly Celgene Corporation), is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma. Sutro&#8217;s proprietary technology was responsible for the discovery and manufacturing of CC-99712, for which Bristol Myers Squibb has worldwide development and commercialization rights. Sutro is entitled to development and regulatory milestone payments and tiered royalties from Bristol Myers Squibb for this BCMA ADC. Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.<\/p>\n<p>To date, Sutro&#8217;s platform has led to cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies directed at precedented targets in clinical indications where the current standard of care is suboptimal. The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.<\/p>\n<p>In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel,\u00a0next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.<\/p>\n<p>Additional multimedia content from Sutro regarding STRO-001 and STRO-002 can be found\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990982-1&amp;h=3783932357&amp;u=https%3A%2F%2Fvimeo.com%2F327114553%2Ff811566729&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a> and\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990982-1&amp;h=3319869671&amp;u=https%3A%2F%2Fvimeo.com%2F327375608%2Fe8143e87fd&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a>.<\/p>\n<p>Follow Sutro on Twitter,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990982-1&amp;h=3005077607&amp;u=https%3A%2F%2Fwww.twitter.com%2FSutroBio&amp;a=%40Sutrobio\" rel=\"nofollow noopener noreferrer\">@Sutrobio<\/a>, and at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990982-1&amp;h=3586905099&amp;u=http%3A%2F%2Fwww.sutrobio.com%2F&amp;a=www.sutrobio.com\" rel=\"nofollow noopener noreferrer\">www.sutrobio.com<\/a>\u00a0to learn more about our passion for changing the future of oncology.<\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of clinical trials and announcements of clinical results, potential benefits of the company&#8217;s product candidates and platform and potential market opportunities for the company&#8217;s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company&#8217;s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company&#8217;s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company&#8217;s business, clinical trial sites, supply chain and manufacturing facilities, the Company&#8217;s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical studies and clinical trials, the company&#8217;s ability to fund development activities and achieve development goals, the company&#8217;s ability to protect intellectual property, and the Company&#8217;s commercial collaborations with third parties and other risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.<\/p>\n<p>\n        <b>Investor Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Annie Chan<\/span><br \/>\n        <br \/>Sutro Biopharma<br \/>650-255-8806 <br \/><a target=\"_blank\" href=\"mailto:ajchang@sutrobio.com\" rel=\"nofollow noopener noreferrer\">ajchang@sutrobio.com<\/a><\/p>\n<p>\n        <b>Media Contacts<br \/><\/b><br \/>\n        <span class=\"xn-person\">David Schull<\/span><br \/>\n        <br \/>Russo Partners<br \/>(212) 845-4271<br \/><a target=\"_blank\" href=\"mailto:david.schull@russopartnersllc.com\" rel=\"nofollow noopener noreferrer\">david.schull@russopartnersllc.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer-301179245.html\">http:\/\/www.prnewswire.com\/news-releases\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer-301179245.html<\/a><\/p>\n<p>SOURCE  Sutro Biopharma<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY01192&amp;Transmission_Id=202011240700PR_NEWS_USPR_____NY01192&amp;DateId=20201124\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Discussion of STRO-002 Data and Program Expansion at 5pm ET \/ 2pm PT on Dec. 3rd &#8211; PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,\u00a0 announced today that it will host a live webcast event to provide a clinical update from the company&#8217;s ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolR\u03b1) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of Oct. 30, 2020. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Discussion of STRO-002 Data and Program Expansion at 5pm ET \/ 2pm PT on Dec. 3rd &#8211; PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,\u00a0 announced today that it will host a live webcast event to provide a clinical update from the company&#8217;s ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolR\u03b1) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of Oct. 30, 2020. The &hellip; Continue reading &quot;Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T12:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer\",\"datePublished\":\"2020-11-24T12:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/\"},\"wordCount\":1120,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY01192&amp;sd=2020-11-24\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/\",\"name\":\"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY01192&amp;sd=2020-11-24\",\"datePublished\":\"2020-11-24T12:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY01192&amp;sd=2020-11-24\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY01192&amp;sd=2020-11-24\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer - Market Newsdesk","og_description":"&#8211; Discussion of STRO-002 Data and Program Expansion at 5pm ET \/ 2pm PT on Dec. 3rd &#8211; PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 \/PRNewswire\/ &#8212;\u00a0Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,\u00a0 announced today that it will host a live webcast event to provide a clinical update from the company&#8217;s ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolR\u03b1) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of Oct. 30, 2020. The &hellip; Continue reading \"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T12:03:29+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer","datePublished":"2020-11-24T12:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/"},"wordCount":1120,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/","name":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24","datePublished":"2020-11-24T12:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY01192&amp;sd=2020-11-24"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}